The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Objective Low glucagon‐like peptide‐1 (GLP‐1) concentrations have been observed in impaired fasting glucose (IFG). It is uncertain whether these abnormalities contribute directly to the pathogenesis of IFG and impaired glucose tolerance. Dipeptidyl peptidase‐4 (DPP‐4) inhibitors raise incretin hormone concentrations enabling an examination of their effects on glucose turnover in IFG. Research design and methods We studied 22 subjects with IFG using a double‐blinded, placebo‐controlled, parallel‐group design. At the time of enrolment, subjects ate a standardized meal labelled with [1‐13 C]‐glucose. Infused [6‐3 H] glucose enabled measurement of systemic meal appearance (MRa). Infused [6,6‐2 H 2] glucose enabled measurement of endogenous glucose production (EGP) and glucose disappearance (Rd). Subsequently, subjects were randomized to 100 mg of sitagliptin daily or placebo. After an 8‐week treatment period, the mixed meal was repeated. Results As expected, subjects with IFG who received placebo did not experience any change in glucose concentrations. Despite raising intact GLP‐1 concentrations, treatment with sitagliptin did not alter either fasting or postprandial glucose, insulin or C‐peptide concentrations. Postprandial EGP (18·1 ± 0·7 vs 17·6 ± 0·8 μmol/kg per min, P = 0·53), Rd (55·6 ± 4·3 vs 58·9 ± 3·3 μmol/kg per min, P = 0·47) and MRa (6639 ± 377 vs 6581 ± 316 μmol/kg per 6 h, P = 0·85) were unchanged. Sitagliptin was associated with decreased total GLP‐1 implying decreased incretin secretion. Conclusions DPP‐4 inhibition did not alter fasting or postprandial glucose turnover in people with IFG. Low incretin concentrations are unlikely to be involved in the pathogenesis of IFG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Normal fasting plasma glucose levels and type 2 diabetes in young men
Tirosh, A., Shai, I., Tekes-Manova, D., Israeli, E., Pereg, D., Shochat, T., Kochba, I., & Rudich, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050080 · Cited by 508 · cited 1×
“Impaired fasting glucose (IFG) confers a high risk of progression to diabetes [1].”
BackgroundVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 1×
“Total and intact GLP-1 and GIP concentrations were measured using C-terminal and N-terminal assays [11,12].”
MethodSelf-citationOral Glucose Tolerance Test Minimal Model Indexes of β-Cell Function and Insulin Sensitivity
Breda, E., Cavaghan, M. K., Toffolo, G., Polonsky, K. S., & Cobelli, C. (2001) · Diabetes · doi:10.2337/diabetes.50.1.150 · Cited by 320
Self-citationWeyer, C., Bogardus, C., & Pratley, R. E. (1999) · Diabetes · doi:10.2337/diabetes.48.11.2197 · Cited by 292
Rosenstock, J., Foley, J. E., Rendell, M., Landin-Olsson, M., Holst, J. J., Deacon, C. F., Rochotte, E., & Baron, M. A. (2008) · Diabetes Care · doi:10.2337/dc07-1616 · Cited by 153
Self-citation
Cited by
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
“DPP4 inhibitors reduce the metabolic inactivation of GLP-1 and increase circulating concentrations of the intact peptide (32, 409).”
BackgroundWeivoda, M. M., Chew, C. K., Monroe, D. G., Farr, J. N., Atkinson, E. J., Geske, J. R., Eckhardt, B., Thicke, B., Ruan, M., Tweed, A. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14003-6 · Cited by 230
Self-citationCobelli, C., Dalla Man, C., Toffolo, G., Basu, R., Vella, A., & Rizza, R. (2014) · Diabetes · doi:10.2337/db13-1198 · Cited by 216
Self-citationUllmer, C., Alvarez Sanchez, R., Sprecher, U., Raab, S., Mattei, P., Dehmlow, H., Sewing, S., Iglesias, A., Beauchamp, J., & Conde‐Knape, K. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12158 · Cited by 92
Hemmingsen, B., Sonne, D. P., Metzendorf, M.-I., & Richter, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012204.pub2 · Cited by 63
Metadata
- Authors
- Bock, G., Man, C. D., Micheletto, F., Basu, R., Giesler, P. D., Laugen, J., Deacon, C. F., Holst, J. J., Toffolo, G., Cobelli, C., Rizza, R. A., & Vella, A.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2010-07-21
- Volume
- 73
- Issue
- 2
- Pages
- 189-196
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2125884659
- Cited by
- 71
- References
- 6
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. https://app.cochat.ai/papers/10.1111/j.1365-2265.2009.03764.x
- The paper
- Bock, G., Man, C. D., Micheletto, F., Basu, R., Giesler, P. D., Laugen, J., Deacon, C. F., Holst, J. J., Toffolo, G., Cobelli, C., Rizza, R. A., & Vella, A. (2010). The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2009.03764.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.